Traditionally, the main model of the pharmaceutical industry for developing new drugs has been based on monotherapies, new molecular entities (NMEs), and their underlying one-target-onedisease dogma. It is no surprise that closely related fields such as the cosmeceutical and nutraceutical areas, largely inspired by Big Pharma, have also mainly used that model. However, compelling evidence suggests that the time has come for these sectors of R&D activities to further explore more efficient, cost-effective and reliable approaches for innovative products. Among a few approaches proposed
INTRODUCTION
Several experts have recently pointed out that the golden age of the pharmaceutical industry is past. Some have even declared that significant changes are needed to support innovation in that area in the future. On average, the cost of developing a new drug (i.e., New Molecular Entities or NMEs), which had substantially increased in the last twenty years, has gone beyond $1.3 billion U.S. dollars in recent years (i.e., including the cost of failures). It takes more time than ever to develop a new therapeuticthat is between 10 and 15 years of development to bring a NME to market [1, 2] . With those significant hurdles, it is less than one product out of five or ten thousands potential candidates that succeeds at reaching market [3] . Consequently, and despite expensive state-of-the-art devices for identifying leads and new candidates, pharmaceutical companies are still not producing drugs any faster than they were before, several decades ago [4] . In fact, less and lessNMEs are approved each year [5] [6] [7] .
In recent years, as an attempt to boost innovation and to accelerate the approval of new products, the great potential of fixed-dose combination (FDC) products has been explored. Because of less stringent regulations, in closelyrelated sectors such as the nutraceutical and cosmeceutical areas, FDCs and its newest evolutionary versions -VDCs and CanSATshave emerged as one of the best solutions for innovative products in the food and skin care industries.
FIXED-DOSE COMBINATION PRODUCTS (FDCs)
According to the U.S. Food and Drug Administration (FDA) and the Federal Food, Drug, and Cosmetic Act (FFDCA), NMEs are products that are composed of an active moiety that has never been approved by the FDA or marketed in the U.S. In clear contrast, products that are composed exclusively of known molecular entities (so-called 'old' drugs) are referred to as combination products (source: www.fda.gov). This said, some combination products mainly include one or several NMEs.
In the pharmaceutical industry, they are particularly referred to as FDCs -that is a final product comprising two or more active ingredients that are combined in a single dosage form (also known as 'polypill' or 'combo pill') for either new effects or superior synergistic-like efficacy with less adverse effects. The World Health Organization (WHO) stated that FDCs have advantages when there is an identifiable patient population for whom treatment with a particular combination of actives in a fixed ratio of doses has been shown to be safe and effective, and when all of the actives contribute to the overall therapeutic effect. In addition, there can be real clinical benefits in the form of increased efficacy and/or reduced incidence of adverse effects [8] .
Since the 1990s, the number of FDCs approved by regulatory authorities has kept augmenting. One hundred and thirty one (131) FDC products have been approved thus far in the U.S. (Table 1 ) [9] . Among them, FDCs for cardiovascular, endocrinological, infectious, neurological and respiratory problems and disorders have been developed and successfully commercialized [9] . In fact, many have become gold-standards in their respective classes.
The FDA has recognized the great potential of FDCs for the future of innovation. Indeed, for
FDCs that comprise at least one NME (also referred to as New Chemical Entity), five years of exclusivity is allowed. In turn, for new FDCs that represents a new use of old drugs, FDA is able to grant three years of patent protection [10] . Pharmaceutical companies are turning toward FDCs not only to increase innovation but also to diffuse the impact of generic competition, revitalize established brands, fill gaps in product pipelines, and enhance patient compliance. Generally, combinations of old molecules carry lower risk and adverse effect issues although high financial reward remains because the resulting product comes with new patents that protect it from generic competition.
The superior efficacy of FDCs has been shown first in the fields of cancer and HIV. According to Jim Kling, science and medical writer for The Washington Post and Scientific American, drug combinations, laboriously worked out in clinical trials, are the key to most cancer treatments [11, 12] . Most drugs, from monoclonal antibodies to small-molecule kinase inhibitors, are most effective in combinations [14] .
On the other hand, the mechanisms of action are often more difficult to identify clearly with FDCs compared with monotherapies (e.g., NMEs). For instance, beyond the known target associated with each active ingredient considered separately (as monotherapies), synergistic actions involved at the cellular and intracellular levels remain more difficult to investigate when all molecules are co-administered as FDCs.
As an example, we discovered a few years ago unsuspected effects induced by a FDC called Spinalon for chronic spinal cord injury cases. A combination of levodopa, carbidopa and buspirone (better known for their effects against Parkinson's tremor and anxiety, respectively) was found to acutely elicit and restore temporarily stereotyped locomotor movements in spinal cord-transected animals [13] . It is currently under clinical development (Phase IIA trials) in spinal cord-injured patients [14] although the detailed mechanism of action at the intracellular level has not been established clearly yet. Indeed, despite clear evidence showing a specific role for dopaminergic and serotonergic targets (D 1 and 5-HT 1A receptors) presumably belonging to neurons of the spinal locomotor network (a.k.a. CPG), interactions between intracellular pathways known to modulate cellular activity upon serotonin and dopamine transmembrane receptor activation remain unclear [15, 16] .
Interestingly, known transmembrane cell targets but unclear intracellular synergistically-acting actions characterize also three (3) additional FDCs composed of different active molecules that were found in our laboratory to selectively restore micturition, defecation and ejaculation, other complex behaviors generally lost or impaired in spinal cord injured-patients [17] [18] [19] . In virtually all cases though, drug-drug combinations developed for therapeutic purposes have been fixed-dose products for simplicity and regulatory reasons. However, in nutraceutical and cosmeceutical areas, where less stringent regulations exist, next-generation combination products have arisen -products for which doses are not fixed and, as such, that may be referred to as variable-dose combinations (VDCs).
NON-FIXED-DOSE COMBINATION PRODUCTS (non-FDCs)
Strictly speaking, non-FDCs have been known for several years. Indeed, non-FDCs include also products for which several specific molecules have not been comprised within a single final product. For instance, they may be assembled in the same package or not. This may be associated to some extent with an older approach called pharmaceutical compounding or traditional compounding where, typically, only form, taste or texture is was changed to fit the unique need of a patient.
The main disadvantage of these other forms of drug combination products is that no patent protection can be sought and, hence, no exclusively of commercialization may be obtained.
The first ever co-packaged combination product was Bristol-Myers's Pravigard PAC that was approved by the FDA in 2003.
A NOVEL HYBRID APPROACH: VARIABLE DOSE COMBINATION PRODUCTS (VDCs)
Beyond, these earlier types of non-FDCs, there is now a few examples of next-generation products that have been marketed recently. Products comprising several active ingredients for which doses are not necessarily fixed. For some of the active ingredients, doses may indeed vary separately and accordingly with the specific segment of the market addressed for each declination of a particular line of products. Probably the best examples of what may be considered as VDCs (terminology introduced for the first time in this article) are multivitamins. Just a few years ago, the vitamin industry was essentially composed of FDCs given that for each brand (e.g., Swiss Naturals® or Centrum®), the recipe was unique and has remained still. More recently, those companies have begun fragmenting their markets in the hope of increasing overall market size and sales. That is how a variety of different Centrum® became commercially available. Centrum® specifically adapted for men or women as well as Centrum® for young active or older people (50+, menopausal women, etc.) became available as over-the-counter products. Essentially, the same ingredients composed every one of these specialty products but doses may slightly vary from one to another. To stimulate innovation for increased sales, those companies went from single-market to market specialization.
A Quebec-based company, Integral Dermo Correction (IDC), has also launched a series of anti-aging products that share a common technological platform called Regen-16® based on a useful combination of sixteen active ingredients aimed at further slowing down different naturally interacting mechanisms of skin physiology associated with aging (source: IDCdermo.com).
The company Neuro Drinks has also tapped into VDCs by offering a variety of drinks essentially composed of the same ingredients but in different doses with specific claims about sleep, energy, or relaxation (www.drinkneuro.com).
A SUBCLASS OF VDCs: CO-ACTIVATION OF NATURAL SYNERGISTICALLY-ACTING TARGET-RECEPTORS (CanSATs)
The cosmetic industry has also entered drastic changes and transformations in recent years. Traditionally, cosmetics have been composed of excipients and non-active ingredients (in the pharmaceutical sense). For instance, for years, moisturizers have been composed of petrolatum jelly as main ingredient (e.g., Vaseline®, Cetaphil®).
As an alternative to surgical interventions aimed to fight the many signs of aging (breast enhancement, fat tissue removal, face lift, etc.), the cosmeceutical industry was born.
Cosmeceutical products emerged as cosmetics that comprise also biologically active ingredients for medical or drug-like benefits. A plethora of expensive anti-aging creams, lotions and serums came up but most often with the classical onetarget-one-disease approach -that is one featured active ingredient among the excipients composing essentially a moisturizing product.
From there, other companies have taken advantage of the main FDC principles -that is co-activation of several targets generally provides more efficacy than activation of just one type of target. For instance, LaBelle Cosmeceuticals based in California has developed dermatological products against premature aging by wisely combining forty different classes of active ingredients that are mainly botanical extracts (source: lbcosmec.com).
The omega supplements market has also been fragmented recently. Vitabiotics, a Norway-based company, has used basically the same recipe of mixed omegas but at different doses for junior, for pregnant women, for women in general or for men. In Canada, Adrien Gagnon has also developed a line of products containing omegas for kids to help brain development, for pregnant women to help brain, eye and nerve development or for elderly to promote general health and cardiovascular function.
Our team (under licensing agreement with a Canadian company) has also developed a VDC adapted to natural product-type of active ingredients, consequently referred to as -CoActivation of Natural Synergistically-Acting Target-receptors (CanSATs). It essentially combines appropriate doses of a wide variety of complex natural products (e.g., shea butter, Labrador tea, canola oil, glycerin, black tea, hyaluronic acid, urea) containing different sets of natural active ingredients (vitamins, minerals, etc.). This approach has been tested clinically to demonstrate superior efficacy compared with positive comparators (e.g., one of the best moisturizer on the market composed essentially of petrolatum jelly and glycerin, https://clinicaltrials.gov/ct2/show/NCT02429206). It is aimed to be declined in several specific specialty products for body and foot ultramoisturizing creams and serums (line of products called SQIN TM ) designed specifically for chronic dry skin (xerosis) in elderly or patients suffering of mobility problems and/or paralysis.
CONCLUSION
The golden era of the pharmaceutical industry is behind us. NMEs and monotherapies are no longer the best approach given the skyrocketed costs and average time required for a new therapeutic molecule to market. One of the most promising approaches to stimulate again innovation and to bring new products to market is the combination product approach. In just a few years, more than a hundred FDCs, VDCs or socalled CanSATs (for natural product combinations) have reached market for cancer, HIV, malaria, tuberculosis, multiple sclerosis, spinal cord injury and for foods (functional foods) and dermatological products (anti-aging, repairing and moisturizing). This may suggest that the future of innovative products in the global health industry is progressively getting brighter again although regulatory changes will have to be made for comparable innovations in the pharmaceutical industry.
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